C.M. Bidwell & Associates’s Bio-Rad Laboratories Class A BIO Stock Holding History

C.M. Bidwell & Associates’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-895	Closed	-$280K	–	396
2018 Q3	$280K	Sell	895 -215	-19%	-$66.7K	0.27%	103
2018 Q2	$320K	Sell	1,110 -2,410	-68%	-$665K	0.3%	92
2018 Q1	$880K	Buy	+3,520	New	+$896K	0.81%	29
2017 Q4	–	Sell	-160	Closed	-$36K	–	401
2017 Q3	$36K	Sell	160 -19,075	-99%	-$4.29M	0.06%	183
2017 Q2	$4.35M	Sell	19,235 -3,290	-15%	-$717K	0.93%	44
2017 Q1	$4.49M	Sell	22,525 -30	-0.1%	-$5.78K	1.01%	31
2016 Q4	$4.11M	Buy	+22,555	New	+$3.85M	0.97%	38
2016 Q3	–	Sell	-1,935	Closed	-$277K	–	259
2016 Q2	$277K	Buy	+1,935	New	+$276K	0.07%	130

Other funds holding BIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

C.M. Bidwell & Associates's BIO Position: Q4 2018 in Review

C.M. Bidwell & Associates sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2018, closing a stake of 895 shares — an estimated $280K sold.

C.M. Bidwell & Associates first reported a position in BIO in Q2 2016 and held it in 8 quarters. The position peaked at $4.49M in Q1 2017. 329 funds tracked by Wall St. Rank hold BIO as of Q4 2018.

C.M. Bidwell & Associates reported no remaining Bio-Rad Laboratories Class A position as of Q4 2018 after selling out during the quarter.
C.M. Bidwell & Associates sold 895 Bio-Rad Laboratories Class A shares in Q4 2018, an estimated $280K.
C.M. Bidwell & Associates first reported a position in Bio-Rad Laboratories Class A in Q2 2016 and held it in 8 quarters.
C.M. Bidwell & Associates's Bio-Rad Laboratories Class A position peaked at $4.49M in Q1 2017.
329 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2018.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2018, filed 14 Feb 2019.